Nuvasive's long-term debt is $550M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2023), NUVA shows a long-term debt of $550M. That compares with $440M in the prior-year period — up 23.1% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, NUVA's long-term debt is now $550M (was $440M) — a 23.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Nuvasive is outperforming or lagging.
Tracking NUVA's long-term debt over time shows whether Nuvasive is scaling, shrinking, or reshaping that part of the business. The current reading is $550M That compares with $440M in the prior-year period — up 23.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Nuvasive's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $550M) with ownership activity and broader fundamentals.
Nuvasive's long-term debt is $550M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.